Spravato Prior Authorization Denied: What to Do Next

Getting a denial letter for Spravato can feel like a door slamming shut right when you were finally ready to move forward. Take a breath. A prior authorization denial is common, it is rarely the final word, and denials are often overturned on appeal, especially with strong documentation. For most patients, a denial is a paperwork hurdle to clear, not a verdict on whether treatment can help you.

Spravato (esketamine) is FDA-approved for treatment-resistant depression, and because it is given in a certified clinic, insurers almost always require prior authorization first. That extra step is exactly where many requests get held up. Below is what a denial usually means, how the appeal path works in Texas, what documentation tends to win, and what NeuroGlow handles on your behalf.

Why Spravato prior authorizations get denied

Most denials are not about whether you need care. They are about whether the paperwork matched the plan’s checklist. The most common reasons we see include:

• Missing two-antidepressant documentation. Many plans define treatment-resistant depression as an inadequate response to at least two different antidepressants, each tried at an adequate dose for an adequate length of time, in the current episode. If the medication names, dosages, dates, and outcomes are not clearly spelled out in the submitted records, the plan often issues a denial even when the history exists.
• Dosing or duration gaps. A prior trial that was stopped early, taken at a low dose, or missing a documented start and stop date may not “count” under the plan’s criteria. These gaps are frequently a records problem rather than a true gap in your treatment history.
• Plan-specific criteria not addressed. Coverage rules vary by plan. Some require a specific diagnosis code, that Spravato be prescribed alongside an oral antidepressant, or that it be delivered in a certified setting. If a request does not speak directly to that plan’s language, it can be denied on a technicality.
• Coding or benefit-routing issues. Sometimes the denial has nothing to do with your clinical story and everything to do with how the claim was coded or which benefit it was routed through.

The encouraging part: nearly all of these are fixable. A denial rooted in documentation can usually be answered with better documentation.

Reading your denial letter: the 3 things to find

Before you do anything else, find your denial letter (it may also be called an “adverse determination” or “notice of non-coverage”) and look for three things:

• The specific reason for the denial. The letter must state why. Look for language like “not medically necessary,” “step therapy not met,” “insufficient documentation,” or “experimental/investigational.” The reason tells you exactly what your appeal needs to answer.
• The appeal deadline. There is a window to file, and it varies by plan. Missing it can cost you the easiest path, so note the date and act early.
• How to appeal and who to call. The letter should list a member-services or appeals phone number, an address or portal for submitting an appeal, and your right to request the plan’s criteria and a copy of the records used in the decision.

Keep the letter, photograph it, and share it with your care team. It is the roadmap for everything that follows. If you are still sorting out how your benefits apply, our overview of how Spravato insurance coverage works and our general insurance page walk through the basics in plain language.

Ready to have someone in your corner? You do not have to decode insurance language alone. NeuroGlow’s team reviews denial letters with patients every week and knows what each major plan tends to ask for. If you just received a denial, you can start with a Spravato consultation and we will look at your letter together.

The appeal process, step by step

Appeals move in stages, and you generally climb the ladder one rung at a time. You do not have to do all of this yourself; much of it is handled by your prescriber and clinic. Here is the path many commercial plans follow.

1. Internal appeal. This is your first formal request asking the plan to reconsider. Your prescriber submits additional records and a letter of medical necessity that directly answers the stated denial reason. Many denials are resolved right here once the missing documentation is supplied.

2. Peer-to-peer review. Often available alongside the internal appeal, a peer-to-peer lets your prescriber speak directly with a physician reviewer at the insurance company. This doctor-to-doctor conversation can clear up misunderstandings that paperwork alone cannot.

3. External review (independent review). If internal appeals do not overturn the denial, you can usually request an external review by an independent organization not connected to your insurer. In Texas, the Texas Department of Insurance oversees a process using an Independent Review Organization (IRO) for eligible medical-necessity denials. An IRO’s physician reviewers look at your case fresh, and in Texas an IRO decision is binding on the health plan for the cases it covers, usually at no charge to you. Timelines and eligibility vary, and some plans (such as certain self-funded employer plans governed by federal rules) follow a different external-review path, so the route depends on your coverage.

Your plan documents will tell you which external-review process applies, and our team can help you identify it.

What a strong letter of medical necessity includes

The letter of medical necessity is the heart of a Spravato appeal. Written by your prescriber, it translates your history into the language the plan’s criteria require, and a strong one generally includes:

• Your diagnosis of treatment-resistant depression (or, where applicable, depressive symptoms with suicidal ideation), with the supporting clinical detail. Our primer on treatment-resistant depression explains how it is defined.
• A clear medication history naming each prior antidepressant, the dose, the dates started and stopped, and why it was inadequate or not tolerated, showing at least the two adequate trials most plans expect.
• Other treatments tried, such as therapy or augmentation strategies, and their outcomes.
• The clinical rationale for Spravato, including that it is an FDA-approved treatment for treatment-resistant depression and why it fits your situation now.
• The treatment plan, including that Spravato will be administered in a REMS-certified clinic under approximately two hours of monitoring with a ride home arranged, and that it will be used alongside an oral antidepressant if the plan requires it.
• A direct response to the denial reason, quoting the plan’s own criteria and showing point by point how you meet them.

The more precisely the letter mirrors the plan’s checklist, the harder it is to deny again.

How NeuroGlow handles appeals for patients

You did not choose Spravato to become an insurance expert. Our team, led by medical director Dr. Aaron Brown, DO, manages the moving parts so you can focus on getting better. On your behalf, we typically:

• Review your denial letter with you and identify the exact reason and deadline.
• Pull together your medication history and clinical records into the format the plan expects.
• Draft and submit the letter of medical necessity and internal appeal.
• Request and conduct a peer-to-peer review when it can help.
• Help you understand your external-review rights, including the Texas IRO path, if earlier steps do not succeed.
• Look into a gap exception when Spravato is not available in-network near you.

Denials are often overturned on appeal, especially with strong documentation, and that documentation is precisely what an experienced clinic brings to the table. If you want to hand this off, call us at 469-218-4410 and we will start with your letter.

Your options if the appeal does not succeed

Even in the less common case where appeals do not overturn a denial, you still have paths to treatment. Our team can help you weigh which one fits your coverage and situation.

• SPRAVATO withMe (for eligible, commercially insured patients). The manufacturer’s savings program can lower out-of-pocket cost on the medication for those who qualify. Eligible, commercially insured patients may pay as little as $10 per treatment for the medication. This commercial savings offer does not apply to patients with Medicare, Medicaid, TRICARE, or other government coverage.
• Johnson & Johnson Patient Assistance Foundation (for the uninsured). Patients who are uninsured, or whose coverage does not meet their needs, may qualify to receive Spravato from J&J at no cost for a period of time if they meet income and residency requirements. Eligibility is determined by the foundation, and our team can point you to the application.
• Self-pay IV ketamine at transparent pricing. IV ketamine is used off-label and is not FDA-approved for depression, but it is an option some patients choose while sorting out coverage. NeuroGlow offers transparent self-pay pricing: a $3,500 six-infusion induction series, a $299/month Thrive Essentials membership (one maintenance infusion, integrative therapy hour or NAD+ IV each month), and $500 booster infusions.

For a fuller breakdown of what treatment can cost with and without coverage, see our guide to how much Spravato costs.

Frequently asked questions

Can I keep treatment going during an appeal?

It depends on your plan and where you are in the process. Some patients pause and wait for a decision, while others continue through a savings program or self-pay so they do not lose momentum. Talk with our team about the safest and most affordable way to bridge the gap in your situation.

How many times can I appeal?

You generally have more than one level. Most plans offer at least one internal appeal, often with a peer-to-peer review, and if that does not overturn the denial you can usually request an external review by an independent organization, such as a Texas IRO for eligible cases. The number of levels and the deadlines vary by plan, so check your denial letter and act before the cutoff.

Does a denial mean I am not a candidate for Spravato?

No. A prior authorization denial is an insurance decision about paperwork and coverage criteria, not a clinical judgment that treatment cannot help you. Candidacy is a medical question decided with our care team at your consultation, and many patients who are initially denied go on to be approved after a well-documented appeal.

Who files the appeal, me or the clinic?

Both can play a role, but you do not have to carry it alone. The letter of medical necessity and clinical documentation come from your prescriber, and at NeuroGlow our team drafts and submits much of the appeal on your behalf, including requesting peer-to-peer reviews. You may still need to sign forms or confirm details along the way.